IOL Chemicals

Why is IOL Chemicals & Pharmaceuticals Ltd falling/rising?

As of N/A, IOL Chemicals & Pharmaceuticals Ltd's stock price has risen to 133.60, driven by a 158.31% increase in net profit and a 4.86% rise in promoter stake, indicating strong confidence in the company's future. The stock has outperformed the Sensex, with a year-to-date increase of 62.43%.

As of N/A, IOL Chemicals & Pharmaceuticals Ltd is experiencing a rise in its stock price, currently at 133.60, reflecting an increase of 2.65 or 2.02%. This upward movement can be attributed to several positive factors. The company has reported a significant growth in net profit of 158.31%, alongside very positive results declared on March 26, which included a notable increase in profit before tax (PBT) and net sales. Specifically, the PBT has grown at 89.7% compared to the previous four-quarter average, and net sales reached their highest at Rs 619.45 crore.<BR><BR>Additionally, the company's promoters have shown increased confidence by raising their stake by 4.86% over the previous quarter, now holding 57.48% of the company. This increase in promoter stake is often interpreted as a strong signal of confidence in the company's future prospects. Furthermore, IOL Chemicals has outperformed the benchmark Sensex, generating a return of 37.79% over the past year, while the Sensex has declined by 6.83% in the same period. The stock has also shown impressive returns over longer periods, with a year-to-date increase of 62.43%.<BR><BR>These factors collectively contribute to the stock's rising price, reflecting strong operational performance and positive market sentiment.

Which are the latest news on IOL Chemicals?

How big is IOL Chemicals?

As of 10th June, IOL Chemicals & Pharmaceuticals Ltd has a market capitalization of 3,957.00 Cr, with recent net sales of 2,319.06 Cr and a net profit of 137.64 Cr. The company's shareholder's funds are 1,687.66 Cr, and total assets amount to 2,382.07 Cr.

As of 10th June, IOL Chemicals & Pharmaceuticals Ltd has a market capitalization of 3,957.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest 4 quarters, the company reported Net Sales of 2,319.06 Cr and a Net Profit of 137.64 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, showing Shareholder's Funds of 1,687.66 Cr and Total Assets of 2,382.07 Cr.

Who are in the management team of IOL Chemicals?

The management team of IOL Chemicals includes Varinder Gupta (Managing Director), Vikas Gupta (Joint Managing Director), Rajender Mohan Malla (Chairman), and several other directors and officers, all responsible for guiding the company's strategic direction and operations.

The management team of IOL Chemicals includes the following key members:<BR><BR>1. **Varinder Gupta** - Managing Director<BR>2. **Vikas Gupta** - Joint Managing Director<BR>3. **Rajender Mohan Malla** - Chairman & Independent Director<BR>4. **Sandhya Mehta** - Non-Executive & Independent Director<BR>5. **Harpal Singh** - Non-Executive & Independent Director<BR>6. **Kushal Kumar Rana** - Director (Works)<BR>7. **Abhiraj Gupta** - Executive Director<BR>8. **Abhay Raj Singh** - Company Secretary & Compliance Officer<BR>9. **Sharad Tyagi** - Independent Director<BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

Who are the peers of the IOL Chemicals?

IOL Chemicals' peers include Bliss GVS Pharma, Orchid Pharma, Guj. Themis Bio., Advanced Enzyme, RPG LifeScience, Gufic BioScience, SMS Pharma, Aarti Drugs, Panacea Biotec, and Zota Health Care. In terms of performance, Bliss GVS Pharma leads with a 1-year return of 185.09%, while IOL Chemicals has a return of 43.27%.

Peers: The peers of IOL Chemicals are Bliss GVS Pharma, Orchid Pharma, Guj. Themis Bio., Advanced Enzyme, RPG LifeScience., Gufic BioScience, SMS Pharma., Aarti Drugs, Panacea Biotec, and Zota Health Care.<BR><BR>Quality Snapshot: Excellent management risk is observed at Bliss GVS Pharma, Guj. Themis Bio., Advanced Enzyme, and RPG LifeScience., while Average management risk is found at IOL Chemicals, Gufic BioScience, SMS Pharma., Aarti Drugs, and Zota Health Care. Below Average management risk is noted for Orchid Pharma and Panacea Biotec. In terms of Growth, Excellent growth is seen at Guj. Themis Bio. and Advanced Enzyme, while Average growth is found at Bliss GVS Pharma, IOL Chemicals, RPG LifeScience., Gufic BioScience, SMS Pharma., Aarti Drugs, and Zota Health Care. Below Average growth is noted for Orchid Pharma, Guj. Themis Bio., and Panacea Biotec. Excellent capital structure is observed at Bliss GVS Pharma, Guj. Themis Bio., Advanced Enzyme, IOL Chemicals, and RPG LifeScience., while Average capital structure is found at Gufic BioScience and SMS Pharma., and Good capital structure is noted for Aarti Drugs. Below Average capital structure is seen at Orchid Pharma and Panacea Biotec.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Bliss GVS Pharma at 185.09%, while the peer with the lowest is Aarti Drugs at -21.25%. IOL Chemicals has a 1-year return of 43.27%, which is significantly higher than Aarti Drugs but lower than Bliss GVS Pharma. Additionally, Orchid Pharma, Advanced Enzyme, and RPG LifeScience. have negative six-month returns.

What does IOL Chemicals do?

IOL Chemicals and Pharmaceuticals Ltd specializes in Active Pharmaceutical Ingredients (APIs) and specialty chemicals, with a market cap of INR 3,957 Cr and a net profit of 53 Cr as of March 2026. The company, established in 1986, operates in the Pharmaceuticals & Biotechnology industry.

Overview: <BR>IOL Chemicals and Pharmaceuticals Ltd is a prominent player in the Active Pharmaceutical Ingredient (API) and specialty chemicals sectors, operating within the Pharmaceuticals & Biotechnology industry and categorized as a Small Cap company.<BR><BR>History: <BR>Incorporated in September 1986, IOL Chemicals has established itself in the pharmaceutical sector. The latest quarterly results reported are for March 2026, showcasing the company's ongoing performance.<BR><BR>Financial Snapshot: <BR>Net Sales: 619 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 53 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 3,957 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 26.00 <BR>Industry P/E: 42 <BR>Dividend Yield: 0.75% <BR>Debt Equity: -0.04 <BR>Return on Equity: 8.12% <BR>Price to Book: 2.17<BR><BR>Contact Details: <BR>Address: Trident Complex, Raikot Road Barnala Sangrur Punjab : 148101 <BR>Tel: 91-01679-244701-07 <BR>Email: contact@iolcp.com <BR>Website: http://www.iolcp.com

Should I buy, sell or hold IOL Chemicals & Pharmaceuticals Ltd?

Are IOL Chemicals & Pharmaceuticals Ltd latest results good or bad?

IOL Chemicals & Pharmaceuticals Ltd reported strong Q4 FY26 results, with a net profit of ₹53.16 crores (up 69.19% year-on-year) and record revenue of ₹619.45 crores (up 17.37% year-on-year), indicating robust operational performance. However, the stock's current high valuation may limit upside potential for new investors.

IOL Chemicals & Pharmaceuticals Ltd has reported impressive results for Q4 FY26, indicating a strong performance. The company achieved a net profit of ₹53.16 crores, which reflects a remarkable 69.19% increase year-on-year and a staggering 158.31% growth compared to the previous quarter. This significant rise in profitability showcases the company's operational improvements and efficiency gains.<BR><BR>Revenue for the same quarter reached ₹619.45 crores, marking a 17.37% year-on-year increase and a 6.73% growth from the previous quarter. This is the highest quarterly revenue in the company's recent history, demonstrating robust demand across its pharmaceutical and specialty chemical segments.<BR><BR>Additionally, the operating margin improved to 14.93%, the highest in seven quarters, indicating effective cost management and enhanced productivity. The company also maintains a zero-debt balance sheet, which provides financial flexibility and stability.<BR><BR>Overall, these results suggest a positive trajectory for IOL Chemicals, showcasing both strong operational performance and financial health. However, the stock is currently trading at a valuation that some may consider "very expensive," which could limit upside potential for new investors. Existing shareholders may want to monitor the stock closely given the impressive quarterly results but should be cautious of the elevated valuations.

When is the next results date for IOL Chemicals & Pharmaceuticals Ltd?

The next results date for IOL Chemicals & Pharmaceuticals Ltd is 20 May 2026.

The next results date for IOL Chemicals & Pharmaceuticals Ltd is scheduled for 20 May 2026.

Has IOL Chemicals & Pharmaceuticals Ltd declared dividend?

Yes, IOL Chemicals & Pharmaceuticals Ltd has declared a 50% dividend, amounting to ₹4 per share, with an ex-date of February 18, 2025. Despite recent volatility, the company has shown positive total returns over the 1-year (8.15%) and 3-year (35.53%) periods.

IOL Chemicals & Pharmaceuticals Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 50%<BR>- Amount per share: 4<BR>- Ex-date: Feb-18-2025<BR><BR>Dividend Yield: 1.05%.<BR><BR>Total Returns by Period:<BR>In the last 3 months, the price return was -23.6%, the dividend return was 1.05%, resulting in a total return of -22.55%.<BR><BR>Over the past 6 months, the price return was -20.07%, the dividend return was 1.06%, leading to a total return of -19.01%.<BR><BR>In the 1-year period, the price return was 6.64%, the dividend return was 1.51%, culminating in a total return of 8.15%.<BR><BR>For the 2-year period, the price return was -6.18%, the dividend return was 6.07%, resulting in a total return of -0.11%.<BR><BR>In the last 3 years, the price return was 18.32%, the dividend return was 17.21%, which led to a total return of 35.53%.<BR><BR>Over the 4-year period, the price return was -7.45%, the dividend return was 21.63%, resulting in a total return of 14.18%.<BR><BR>In the 5-year span, the price return was -44.32%, the dividend return was 16.35%, leading to a total return of -27.97%.<BR><BR>Overall, IOL Chemicals & Pharmaceuticals Ltd has declared a substantial dividend, and while the recent total returns have shown volatility, the company has managed to provide positive returns over longer periods, particularly in the 1-year and 3-year spans.

How has been the historical performance of IOL Chemicals?

IOL Chemicals has experienced a declining trend in net sales and profits over the past few years, with net sales dropping from 2,217.11 Cr in March 2023 to 2,079.21 Cr in March 2025, and profit after tax decreasing from 134.43 Cr to 101.07 Cr in the same period. Despite this, total assets increased to 2,382.07 Cr in March 2025.

Answer:<BR>The historical performance of IOL Chemicals shows a declining trend in net sales and profits over the past few years.<BR><BR>Breakdown:<BR>IOL Chemicals reported net sales of 2,079.21 Cr in March 2025, down from 2,132.79 Cr in March 2024 and 2,217.11 Cr in March 2023, indicating a consistent decrease in revenue. Total operating income mirrored this decline, with figures of 2,079.21 Cr in March 2025 compared to 2,132.79 Cr in the previous year. The total expenditure, excluding depreciation, also decreased to 1,876.91 Cr in March 2025 from 1,902.20 Cr in March 2024. Operating profit (PBDIT) fell to 224.71 Cr in March 2025, down from 260.66 Cr in March 2024, while profit before tax decreased to 137.96 Cr from 181.65 Cr. Consequently, profit after tax was 101.07 Cr in March 2025, a decline from 134.43 Cr in March 2024. The company's total assets increased to 2,382.07 Cr in March 2025 from 2,244.40 Cr in March 2024, while total liabilities also rose to 2,382.07 Cr from 2,244.40 Cr. Cash flow from operating activities was 178.00 Cr in March 2025, down from 289.00 Cr in March 2024, but net cash inflow improved to 70.00 Cr from 6.00 Cr. Overall, the financial metrics reflect a challenging period for IOL Chemicals, characterized by declining sales and profits despite an increase in total assets.

Is IOL Chemicals technically bullish or bearish?

As of October 9, 2025, IOL Chemicals exhibits a mildly bullish trend supported by MACD and Bollinger Bands, though tempered by a mildly bearish KST and Dow Theory signals on the weekly chart.

As of 9 October 2025, the technical trend for IOL Chemicals has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by weekly and monthly MACD indicators both showing bullish signals. The Bollinger Bands also reflect a mildly bullish trend in both time frames. However, the KST indicates a mildly bearish stance on the weekly chart, and Dow Theory shows a mildly bearish trend on the weekly level with no trend on the monthly. The daily moving averages are mildly bullish, but the overall strength is tempered by the recent price action, including a decline from the previous close.

Who are the top shareholders of the IOL Chemicals?

The top shareholders of IOL Chemicals include Maya Devi Polycot Limited with 21.54%, Vasudeva Commercials Limited at 7.94%, and individual investors holding 31.43%. Mutual funds hold 0.02%, while Foreign Institutional Investors (FIIs) account for 1.47%.

The top shareholders of IOL Chemicals include the promoters, who hold a significant majority. The promoter with the highest holding is Maya Devi Polycot Limited, which owns 21.54% of the shares. Additionally, the highest public shareholder is Vasudeva Commercials Limited, holding 7.94%. Individual investors collectively hold 31.43% of the shares, while mutual funds have a minor stake through six schemes, accounting for 0.02%. Foreign Institutional Investors (FIIs) hold 1.47% of the company through 47 different entities.

Is IOL Chemicals overvalued or undervalued?

As of May 19, 2025, IOL Chemicals is considered very expensive and overvalued compared to its peers, with key financial ratios significantly higher and lower returns, making it an unfavorable investment despite a recent strong performance.

As of 19 May 2025, the valuation grade for IOL Chemicals has moved from fair to very expensive. The company is currently overvalued based on its financial metrics. Key ratios include a PE ratio of 25.73, an EV to EBITDA of 12.39, and a Price to Book Value of 1.54, which are significantly higher than many of its peers.<BR><BR>In comparison, Solar Industries has a PE ratio of 123.77 and an EV to EBITDA of 76.22, while Godrej Industries, which is rated attractive, has a PE ratio of 46.63 and an EV to EBITDA of 34.36. These comparisons highlight that IOL Chemicals is not only overvalued relative to its peers but also lacks competitive returns, with a ROE of 5.99% and a ROCE of 8.18%. Despite a strong 1-month return of 42.94% compared to the Sensex's 3.88%, the overall valuation indicates that IOL Chemicals is not a favorable investment at this time.